Why the study?
Does tailored use of new oral anticoagulants compared to warfarin improve the benefit/risk ratio in patients requiring anticoagulation?
Does tailored use of new oral anticoagulants compared to warfarin improve the benefit/risk ratio in patients requiring anticoagulation?
This review highlights the need for a tailored approach to oral anticoagulation, balancing the benefits and risks of new oral anticoagulants versus traditional warfarin for specific patient subpopulations.
Supports individualized anticoagulation strategies; leaves open optimal NOAC-warfarin selection pending prospective data.
Warfarin is the most widely used oral anticoagulant and has been available for more than 65 years. The last decade has brought a host of new orally available anticoagulants with promising features to clinical trials and some have already been approved for limited indications. As patients are starting to be switched to these new agents there is a need to gain understanding of the subsets of patients that will benefit the most from the new alternatives and whether warfarin is still the best choice for some subpopulations. With this knowledge we will provide the individual patient with the drug that has the best benefit/risk ratio at the same time as we conserve drug expenditures. This review discusses the directions we could follow in such a tailored anticoagulation approach, referring to the limited evidence when available.
No takes yet. Share an insight, caveat, or question.
Sam Schulman (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: